Micardis® in Patients With Essential Hypertension
HypertensionThe aim of this observational study was to supplement the data on efficacy, safety, and tolerability of telmisartan under daily conditions in hospitals
FimasaRtan-basEd BP Targets After Drug SwitcHing
Essential HypertensionThe recent hypertension clinical practice guidelines published by American College of Cardiology (ACC) and American Heart Association (AHA) reduced the target BP to 130/80 mmHg, indicating the needs for more aggressive efforts in hypertension treatment. However, studies in Koreans must be preceded before applying such new overseas guidelines; thus, this study has been designed to establish clinical materials reflecting treatment setting in Korea. In this study, patients with uncontrolled hypertension whose antihypertensive regimens are changed to ARB-based therapy (ARB monotherapy or ARB-containing combination therapy) will be followed to assess the treatment trend, treatment effect, and risk of cardiovascular disease.
Effect of Aerobic Exercise in Patients With Essential Hypertension
Aerobic ExerciseEssential HypertensionThe goal of this observational study is to evaluate the effects of a supervised aerobic exercise training program on weight loss, functional capacity, quality of life (QoL), and depression levels in patients with essential hypertension.
Post-Authorization Long-term Safety Surveillance on Antihypertensive Treatment With Kanarb® (Fimasartan)...
Essential HypertensionEvaluated the incidence and characteristics of adverse events during the treatment for Kanarb tablet.
Observation of the Efficacy and Tolerance of Motens® (Lacidipine) in Patients With Essential Hypertension...
HypertensionStudy of the efficacy and tolerance of Motens® (lacidipine) in patients with essential hypertension. To obtain information on the dosage used in practice and the tolerance at the start of treatment (12 weeks)
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in Hospitals...
HypertensionThe aim of the observational study was to supplement the data on efficacy, safety and tolerability of telmisartan under daily conditions in hospitals
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting...
Primary HypertensionOne of the most common adverse effects resulting from the therapy with thiazides, thiazide-like diuretics and loop diuretics is increased potassium secretion. Disregulation of plasma potassium may be a life-threatening condition due to increased risk of arrythmias. Moreover, it has been postulated that decrease in plasma potassium level may negatively affect glucose metabolism resulting in the increased risk of new-onset type 2 diabetes.The main goal of this study is to assess the efficacy and safety of telmisartan/hydrochlorothiazide in a broad population of hypertensive patients, including the effects of the therapy on plasma potassium level and also on selected parameters of glucose and lipid metabolism.
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Essential HypertensionThe purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
PheochromocytomaParaganglioma1 morePheochromocytoma or paraganglioma are tumors generating hypertension as a symptom. Different biological tests are currently available to diagnose these tumors. However, they all lack specificity since they do not distinguish cases of hypertension without pheochromocytoma or paraganglioma. To improve the diagnostic specificity of these tumors, the investigators are testing a new marker called EM66.
Using Telmisartan Alone or Combination of Telmisartan -HCTZ in the Treatment of Mild to Moderate...
HypertensionThe aim of this therapeutic observation is to demonstrate the efficacy and safety of telmisartan or telmisartan and HCTZ in the treatment of patients with mild-to-moderate essential hypertension under normal conditions of use after market launch.